Pacific Biosciences Of California (PACB) Return on Invested Capital (2022 - 2024)
Pacific Biosciences Of California's (PACB) quarterly Return on Invested Capital came in at 0.02% in Q2 2024, down 162.99% quarter-over-quarter from 0.01% in Q1 2024.
Pacific Biosciences Of California (PACB) Return on Invested Capital (2022 - 2024) Analysis & Trends
Pacific Biosciences Of California's Return on Invested Capital history runs 3 years deep, the most recent figure standing at 0.02% for Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROIC (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 0.01% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 0.01% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 0.01% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 0.00% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | - |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | - |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 0.00% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 0.00% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Pacific Biosciences Of California | 428.15 Mn | 152.18 Mn | 12.84 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | -0.02% |
| Mar 31, 2024 | -0.01% |
| Dec 31, 2023 | -0.01% |
| Sep 30, 2023 | -0.01% |
| Sep 30, 2022 | -1.78% |